老年急性髓系白血病患者的演变趋势与结局:包括异基因干细胞移植
该回顾性单中心研究纳入2012至2021年新诊断的≥60岁急性髓系白血病患者1073例,中位年龄71岁,分析低强度治疗(LIT)和干细胞移植(SCT)的趋势与结局。LIT联合维奈克拉的复合完全缓解率为72%,高于单用LIT的48%(p<.0001),与强化化疗的74%相当(p=.6)。前线SCT患者2年总生存率为59%,经界标分析,接受前线SCT者总生存优于未接受SCT的缓解患者(中位39.6 vs 21.4个月,p<.0001)。
要点
- LIT联合维奈克拉的复合完全缓解率为72%,高于单用LIT的48%(p<.0001),与强化化疗的74%相当(p=.6)。
- 强化化疗、LIT和LIT联合维奈克拉的中位总生存分别为20.1、8.9和12.1个月。
- 前线SCT(n=139)的2年总生存率、无复发生存率、复发累积发生率和治疗相关死亡累积发生率分别为59%、52%、27%和22%。
核心结论
- 随着更有效的低强度治疗的应用,老年急性髓系白血病患者的结局正在改善。
- 作者认为应采取措施提高老年患者接受干细胞移植的可及性。
研究设计与样本
- 回顾性单中心研究,纳入2012至2021年新诊断的≥60岁急性髓系白血病患者1073例,中位年龄71岁。
- 分析低强度治疗和干细胞移植相关的趋势与结局。
主要发现
- 16%的患者接受强化化疗,51%接受单用低强度治疗,32%接受低强度治疗联合维奈克拉。
- 低强度治疗联合维奈克拉的复合完全缓解率为72%,高于单用低强度治疗的48%(p<.0001),与强化化疗的74%相当(p=.6)。
- 强化化疗、低强度治疗和低强度治疗联合维奈克拉的中位总生存分别为20.1、8.9和12.1个月。
- 18%的患者接受了干细胞移植;强化化疗、低强度治疗和低强度治疗联合维奈克拉组接受干细胞移植的比例分别为37%、10%和22%。
- 前线干细胞移植(n=139)的2年总生存率、无复发生存率、复发累积发生率和治疗相关死亡累积发生率分别为59%、52%、27%和22%。
关键数值与推荐
- 低强度治疗联合维奈克拉的复合完全缓解率为72%,高于单用低强度治疗的48%(p<.0001),与强化化疗的74%相当(p=.6)。
- 强化化疗、低强度治疗和低强度治疗联合维奈克拉的中位总生存分别为20.1、8.9和12.1个月。
- 前线干细胞移植(n=139)的2年总生存率、无复发生存率、复发累积发生率和治疗相关死亡累积发生率分别为59%、52%、27%和22%。
- 经界标分析,接受前线干细胞移植的患者总生存(中位39.6 vs 21.4个月,p<.0001)和无复发生存(中位30.9 vs 12.1个月,p<.0001)优于未接受移植的缓解患者。
临床怎么用
- 作者认为应采取措施提高老年患者接受干细胞移植的可及性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor. Given advances in low-intensity therapy (LIT) and stem cell transplantation (SCT), we performed a retrospective single-center study to evaluate the contemporary outcomes of this population. We reviewed all patients ≥60 years with newly diagnosed AML between 2012 and 2021 and analyzed treatment and SCT-related trends and outcomes. We identified 1073 patients with a median age of 71 years. Adverse clinical and cytomolecular findings were frequent within this cohort. In total, 16% of patients were treated with intensive chemotherapy, 51% with LIT alone, and 32% with LIT plus venetoclax. The composite complete remission rate with LIT plus venetoclax was 72%, which was higher than with LIT alone (48%, p < .0001) and comparable to intensive chemotherapy (74%, p = .6). The median overall survival (OS) with intensive chemotherapy, LIT, and LIT plus venetoclax was 20.1, 8.9, and 12.1 months, respectively. 18% of patients received SCT. SCT rates were 37%, 10%, and 22% in patients treated with intensive chemotherapy, LIT, and LIT plus venetoclax, respectively. The 2-year OS, relapse-free survival (RFS), cumulative incidence (CI) of relapse, and CI of treatment-related mortality with frontline SCT (n = 139) were 59%, 52%, 27%, and 22%, respectively. By landmark analysis, patients undergoing frontline SCT had superior OS (median 39.6 vs. 21.4 months, p < .0001) and RFS (30.9 vs. 12.1 months, p < .0001) compared with responding patients who did not. Outcomes in older patients with AML are improving with more effective LIT. Measures should be pursued to increase access to SCT in older patients.
引用
- Bazinet A, Kantarjian H, Arani N, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023. PMID: 37334870. doi:10.1002/ajh.26997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。